Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?

M. S. Rémond*, A. Pellat, C. Brezault, M. Dhooge & R. Coriat

Department of Gastroenterology, Cochin Hospital, Université de Paris, Assistance Publique-Hôpitaux de Paris, Paris, France

Metastatic pancreatic ductal adenocarcinoma (PDAC) is a major health burden due to its increasing incidence and poor prognosis. PDAC is characterized by a low tumor mutational burden, and its molecular pathogenesis is driven by Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations. Response to DNA damage through homologous repair is defective in 15% of tumors. Chemotherapy using FOLFIRINOX (folinic acid, fluorouracil, irinotecan, oxaliplatin) or gemcitabine-nab-paclitaxel significantly improves life expectancy, but the median overall survival remains <1 year. Targeted therapies are not efficient in the overall population of patients with metastatic PDAC. Improvements in overall survival or progression-free survival, however, have been demonstrated in subgroups carrying certain mutations. Maintenance therapy with poly-ADP-ribose polymerase (PARP) inhibitors increases progression-free survival in patients with germline mutations in BRCA1/2. Sotorasib shows signs of efficacy against tumors carrying the KRAS G12C mutation, and targeted therapies may also benefit patients with KRAS-wild-type PDAC. Combining targeted therapies with chemotherapy holds promise because of potential synergistic effects. These associations, however, have not yet demonstrated clinical benefit. Checkpoint inhibitors are not effective against metastatic PDAC. Combined immunotherapies attempt to restore their efficacy but have not succeeded yet. Other immunotherapies are emerging such as therapeutic vaccines or chimeric antigen receptor (CAR) T cells, but these strategies remain to be evaluated in large trials. In the future, treatment personalization based on tumor-derived organoids could potentially further improve treatment efficiency.

Key words: pancreatic adenocarcinoma, targeted therapies, immunotherapy, precision oncology

INTRODUCTION

Pancreatic ductal adenocarcinoma (PDAC) is currently the fourth deadliest cancer in Europe, causing 132 000 deaths in 2020. The incidence of PDAC is rising in Europe and Southeast Asia, and to a lesser extent in North America. In Europe, it should become the second cause of death by cancer by 2030.

According to the American SEER database, the overall survival (OS) rate of patients diagnosed with PDAC is 10.8% 5 years after diagnosis. Fewer than 15% of patients have a localized disease at diagnosis, allowing a surgical removal of the tumor. Nevertheless, the 5-year OS does not exceed 41% in localized tumors, due to local or distant recurrence. Some 30% of patients have a locally advanced disease at diagnosis, with a 14.4% OS rate at 5 years. This rate drops to 3.0% in patients with distant metastases at diagnosis. PDAC is one of the most aggressive cancers of the gastrointestinal tract and represents a growing public health concern.

Recently, the rise of genomics allowed clinicians to quantify the mutational burden associated with PDAC. These studies identified the key signaling pathways involved in the disease. They also highlighted the profound genomic heterogeneity of PDAC. This improved understanding of the molecular pathogenesis possibly holds the key for the development of targeted therapies in PDAC. In parallel, immunotherapy has attracted much attention because checkpoint inhibitors have proven efficient against numerous solid tumors.

In the present review, the role of non-targeted therapies is discussed in the era of metastatic PDAC. We will then describe the molecular alterations found in metastatic PDAC, and the corresponding targeted therapies, evaluated alone or in combination with chemotherapy. Finally, we will examine the existing data on immunotherapy in metastatic PDAC, and describe alternative strategies currently tested in clinical trials.
Non-targeted therapies approved in metastatic PDAC

The first systemic therapy that demonstrated an effect on survival in PDAC was gemcitabine. Gemcitabine is a pyrimidine nucleoside analog: it blocks DNA synthesis, leading to the death of replicating cells. In 1997, a randomized trial evaluated gemcitabine (1000 mg/m² once weekly, for 3 consecutive weeks out of every 4 weeks) against 5-fluorouracil (5-FU) in patients with advanced or metastatic PDAC. The median OS was 5.65 and 4.41 months for gemcitabine and 5-FU, respectively (P = 0.0025). The survival rate at 12 months was 18% for gemcitabine and 2% for 5-FU.

Since then, two regimens have shown relatively similar outcomes in metastatic PDAC. Nab-paclitaxel is a microtubule inhibitor, bound to an albumin nanoparticle to increase its bioavailability. In metastatic PDAC, nab-paclitaxel (125 mg/m²) was evaluated in combination with gemcitabine (1000 mg/m²) on days 1, 8, and 15 every 4 weeks. The median OS was 8.5 months for doublet chemotherapy compared with 6.7 months for gemcitabine. FOLFIRINOX, a combination therapy of 5-FU, irinotecan, and oxaliplatin, is a three-drug regimen designed to prolong its systemic circulation while minimizing toxicity. In patients progressing after a gemcitabine-based chemotherapy, nab-paclitaxel demonstrated a survival benefit compared with 5-FU alone (P < 0.001). Altogether, FOLFIRINOX and gemcitabine plus nab-paclitaxel are the two first-line regimens commonly used in patients fit enough to receive treatment.

Liposomal irinotecan (n-al-I) is a formulation of irinotecan designed to prolong its systemic circulation while minimizing toxicity. In patients progressing after a gemcitabine-based therapy, the combination of n-al-I + 5-FU (nal-I 80 mg/m², 5-FU 2400 mg/m², and LV 400 mg/m² every 2 weeks) demonstrated a survival benefit compared with 5-FU alone (5-FU 2000 mg/m² plus LV 200 mg/m² weekly for the first 4 weeks of 6-week cycles). Median OS was 6.2 and 4.2 months in the experimental and 5-FU arms, respectively. Consequently, n-al-I + 5-FU was approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as a second-line therapy in metastatic PDAC. The choice of the comparator and dose differences in 5-FU/LV between the two groups, however, prevent a large use of this association in clinical practice.

In a nutshell, chemotherapy has proven some efficacy in metastatic PDAC: it increases median OS by a few months. The survival rate at 5 years, however, remains <5%, demonstrating the urgent need for new therapies.

TARGETED THERAPIES

Molecular alterations in metastatic PDAC

Several studies investigated the genomic complexity of PDAC. The tumor mutational burden (TMB) is defined as the number of mutations per megabase of DNA (m/Mb). Among gastrointestinal cancers, PDAC has the lowest mutational load with a median TMB of 1.1 m/Mb, compared with 3.7 for colon cancer or 13 for melanoma. TMB, however, is highly variable between individuals. Values >10 m/Mb are associated with increased survival in patients receiving checkpoint inhibitors, at least in certain tumors. In a study on 1021 PDAC patients, 0.5% had a TMB >20 m/Mb, whereas 12.4% had a TMB between 5 and 20 m/Mb.

The genomic landscape of PDAC is dominated by a small number of oncogenes. Only five genes are mutated in >10% of PDACs: Kirsten rat sarcoma viral oncogene homolog (KRAS) (88%-92%), TP53 (75%), CDKN2A (44%), SMAD4 (22%), and CDKN2B (21%). These five genes are followed by a long tail of infrequently mutated genes. The most affected intracellular processes are mitogen-activated protein (MAP) kinases (92% of PDACs), cell cycle (>90%), DNA homologous repair (14%-15%), phosphoinositide-3-kinase-AKT (PI3K-AKT) signaling (10%-19%), and chromatin remodeling (15%). Table 1 reports the most common mutations in PDAC. Key signaling pathways involved in PDAC are shown in Figure 1.

KRAS is a GTPase that transduces signal from tyrosine kinase receptors [epidermal growth factor receptor (EGFR), Table 1. Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or molecular process. Prevalence is reported as % of total PDAC patients. These statistics are adapted from 2 sources: A) an international cohort of 3594 PDAC patients undergoing targeted genomic profiling, and B) a targeted genomic screening of 640 patients treated for pancreatic cancer, of which 591 had an histologically confirmed pancreatic adenocarcinoma.

| Pathway | Gene | % |
|---------|------|---|
| MAP kinases (92%) | KRAS | 88-92 |
|  | BRAF | 2 |
|  | ERBB2 | 2.8-3 |
|  | EGFR, FGFR2, MET, MAP2K4, ERBB3, FGFR1, RAF1, ALK, RET, NTRK1 | <1 each |
| PI3K/AKT (10%-19%) | STK11 | 3-4.7 |
|  | PIK3CA | 3-3.7 |
|  | AKT2 | 3 |
| DNA homologous recombination (14%-15%) | BRCA2 | 2.9-4 |
|  | ATM | 3-4.5 |
|  | BRCA1, PALB2, FANCA/C/G | <2 each |
| Cell cycle control (>90%) | TP53 | 74-75 |
|  | CDKN2A | 44-45 |
|  | CDKN2B | 21 |
|  | CCNE1 | 3 |
|  | CHEK1/2 | <2 each |
| Chromatin remodeling (15%) | ARID1A | 8 |
|  | KDM6A | 3 |
|  | DNMT3A | 3 |
| WNT pathway (5%) | RNF43 | 3 |
|  | APC | 2 |
| TGF-8 signaling (22%) | SMAD4 | 22 |
| Other genes | GATA6 | 5 |
|  | GNAT5 | 3 |
|  | MYC | 5 |

MAP, mitogen-activated protein; PDAC, pancreatic ductal adenocarcinoma; PI3K, phosphoinositide-3-kinase; TGF, transforming growth factor; WNT, wingless-related integration site.
fibroblast growth factor receptor 2 (FGFR2)...

...The active, guanosine triphosphate (GTP)-bound form of KRAS stimulates cell growth by activating the MAP kinases and PI3K/AKT pathways. Most KRAS mutations involve amino acid substitutions at the G12 position, which decrease the intrinsic GTPase activity, resulting in prolonged KRAS activation.

KRAS mutations are the signature event of PDAC, with a frequency of 88%-92%. They occur at an early stage of the disease. The most common are G12D and G12V, found in 44%-48% and 28%-29% of KRAS-mutated PDACs, respectively.10,16 KRAS wild-type PDAC is associated with a better prognosis in most studies. For example, in a retrospective cohort of 235 patients, KRAS wild-type status was associated with a 62% decreased hazard of death [hazard ratio (HR) = 0.38, P = 0.016].16 Similar findings were reported in a retrospective cohort of 741 patients with locally advanced or metastatic disease (HR = 1.26 for mutant versus wild-type KRAS).17

Mutations affecting the MAP kinases downstream of KRAS are also frequent in PDAC. They are enriched in KRAS wild-type PDACs, with a prevalence of 25%-38%.15 The most frequently affected gene is v-Raf murine sarcoma viral oncogene homolog B (BRAF): BRAF is mutated in 10% of KRAS wild-type and 0.5% of KRAS-mutated tumors (20-fold enrichment).15,18 BRAF is a kinase activated immediately downstream of KRAS. The most frequent mutations involving BRAF are: gene fusions (31% of BRAF-mutated PDACs), V600E (21%), and a deletion in exon 11 (21% of BRAF-mutated PDACs).19 Other mutations activating MAP kinase signaling in KRAS wild-type PDACs include EGFR (4.3%), ERBB2 (3.4%), and MAP2K1 (2%). Altogether, gene fusions are found in 12% of KRAS wild-type tumors. They are mutually exclusive and are absent in KRAS-mutated cancers. These fusions predominantly involve FGFR2 (4.1% of KRAS wild-type PDACs), BRAF (2.4%), ALK (1.7%), RET, and neurotrophic tyrosine kinase (NTRK).15

Wnt is a signaling pathway involved in cell differentiation. In cancers, it stimulates proliferation and facilitates epithelial-to-mesenchymal transition. Mutations impairing the Wnt pathway are found in 5% of PDAC. These are mostly loss of function mutations in Wnt inhibitors, such as RNF43 (3%) or adenomatous polyposis coli (APC) (2%).

SMAD4 is among the most mutated genes in PDAC, with a prevalence of 22%. SMAD4 is part of the transforming growth factor-β (TGF-β) cascade, a pathway involved in the negative regulation of proliferation. Mutations affecting other genes of the TGF-β pathway are infrequent in PDAC.

Mismatch repair (MMR) is a cellular machinery involved in repairing mismatches or small insertions/deletions in DNA. Deficient MMR (dMMR) results from a mutation or a methylation leading to loss of expression of an MMR protein (MLH1, PMS2, MSH2/6). dMMR is clinically relevant because it predicts sensitivity to checkpoint inhibitors in various tumors. dMMR is uncommon in PDAC, however, affecting only 0.1%-0.8% of patients.15
Homologous repair is involved in the repair of DNA double-strand breaks. It is an alternative to non-homologous end joining (NHEJ). Whereas homologous repair replaces damaged DNA ad integrum, however, NHEJ introduces mutations and translocations. In homologous repair-deficient tumors, recurrent NHEJ promotes oncogenesis by favoring mutations in oncogenes. Mutations in \textit{BRCA1} or \textit{BRCA2} are the most common cause of homologous repair deficiency, but other genes can be involved (\textit{PALB2}, \textit{FANCJ}, \textit{FANCN}). The genomic instability resulting from deficient homologous repair is called BRCAness. Contrary to microsatellite instability (MSI) for MMR-deficient tumors, there is no consensus definition for BRCAness, even though signatures have been proposed.\textsuperscript{21} The most widespread approach is to search for mutations in a panel of homologous repair genes. In PDAC, the overall prevalence of these mutations is 14%-15%, and they predominantly affect \textit{BRCA2} (4%), \textit{BRCA1} (2%), and \textit{PALB2}.\textsuperscript{15,22} Mutations in \textit{BRCA2}/1 are more common in younger patients (<50 years).\textsuperscript{15} Ataxia telangiectasia mutated (\textit{ATM}), a homologous repair activator, is mutated in 3-4%, 5% of PDACs. In a cohort of 276 patients with metastatic PDAC, mutations in \textit{BRCA} or \textit{ATM} had no impact on 1-year OS.\textsuperscript{23}

Among the genomic alterations observed in PDAC, a large majority result from somatic mutational events. Several hereditary syndromes are associated with PDAC, such as: the hereditary breast and ovary cancer syndrome (HBOC) resulting from germline mutations in \textit{BRCA1}/2, the familial atypical multiple mole melanoma (FAMMM) syndrome, caused by mutations in \textit{CDKN2A}, and Peutz-Jeghers syndrome, resulting from mutations in \textit{STK11}. The absolute risk of PDAC of a 70-year-old patient with HBOC reaches 2%-10%, compared with 5%-25% for FAMMM and 36% for Peutz-Jeghers. Other entities, such as Lynch syndrome, are associated with an increased incidence of PDAC, but the absolute risk remains low. A recent study in 250 PDAC patients revealed that 15% carry a pathogenic germline variant; 68% of these variants affect DNA homologous repair.\textsuperscript{24} \textit{BRCA2} harbors the highest rate of germline mutations (3% of total PDAC patients), followed by \textit{ATM}, \textit{CDKN2A}, \textit{APC}, and \textit{BRCA1}.\textsuperscript{15} Among all mutations affecting the homologous repair machinery, 54% are germline.\textsuperscript{15}

The dysregulation of the cell cycle is central to PDAC pathogenesis: mutations affecting this process are found in >90% of PDACs. Figure 2 summarizes the actors of cell cycle regulation involved in the pathogenesis of PDAC. \textit{TP53} is the second most frequently mutated gene in PDAC (74%-75% of PDACs). It encodes P53, a transcription factor and tumor suppressor that prevents cells with damaged DNA from proliferating. Upon detection of DNA damage, P53 is phosphorylated, which prevents its degradation. Accumulation of P53 induces cell cycle arrest at the G1/S checkpoint and activates DNA repair. In the absence of efficient DNA repair, persisting activation of P53 induces apoptosis.

Other cell cycle genes mutated in PDAC are \textit{CDKN2A} (44%-45%), \textit{CDKN2B} (21%), and \textit{CCNE1} (3%). \textit{CDKN2A} encodes P14 and P16, two proteins involved in the response to damaged DNA. P16 inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), thereby blocking the transition from G1 to S phase. P14 contributes to cell cycle arrest by promoting the accumulation of P53.

Chromatin remodeling through DNA methylation and histone modifications is a key mechanism for the control of gene expression. Mutations affecting these processes are found in 15% of PDACs: the most frequent involve \textit{ARID1A} (8%), \textit{KDM6A} (3%), and \textit{DNMT3A} (3%).\textsuperscript{15} \textit{ARID1A} is a subunit of SWI/SNF, a chromatin remodeling complex. In a recent retrospective study on 3728 PDAC patients, mutations in the SWI/SNF system were found in 6.1% of tumors and were predictive of a worse prognosis (HR = 0.78, P < 0.00001).\textsuperscript{25} \textit{KDM6A} is a histone demethylase, whereas \textit{DNMT3A} functions as a DNA methyltransferase: these enzymes maintain methylation patterns involved in the control of gene expression.

**Targeted therapies as monotherapy.** Understanding these molecular events has led clinicians to evaluate targeted therapies in metastatic PDAC. \textbf{Table 2} presents ongoing trials on targeted therapies as monotherapy in metastatic PDAC.

**Cell proliferation and survival.** Targeted therapies inhibiting tyrosine kinase receptors or MAP kinases have been developed since the early 2000. They have shown no benefit, however, in PDAC patients not selected for specific

---

**Figure 2.** Interplay between DNA damage response and cell cycle control in PDAC. This figure shows the main signaling pathways involved in DNA damage response, and how they connect with cell cycle checkpoints. Genes frequently mutated in PDAC are written in italics. Targeted therapies and chemotherapies currently evaluated in PDAC are depicted, together with their molecular targets. CDK, cyclin-dependent kinase; NHEJ, non-homologous end joining; PARP, poly-ADP-ribose polymerase; PDAC, pancreatic ductal adenocarcinoma.

---

\[\text{https://doi.org/10.1016/j.esmoop.2022.100638}\]

Volume 7 ▪ Issue 6 ▪ 2022
molecular alterations. This inefficiency could result from the genomic heterogeneity of PDAC, or from the rapid emergence of resistance. To overcome this limitation, most of the ongoing trials evaluating tyrosine kinases inhibitors in PDAC are using either multitarget inhibitors, or associations of several inhibitors. As an example, a phase I trial evaluates the combined use of trametinib, a MEK1/2 inhibitor, and ruxolitinib, a JAK1/2 inhibitor, in KRAS-mutated metastatic PDAC (NCT04303403). A phase II trial testing the association of vemurafenib, a BRAF inhibitor, with sorafenib, a multitarget tyrosine kinase inhibitor known to inhibit mainly vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) is ongoing (NCT05068752). This non-randomized phase II trial enrolls patients with KRAS G12D-mutated metastatic PDAC who progressed after at least two lines of systemic therapy.

As described previously, the PI3K/AKT pathway is a relevant target in PDAC. Idelalisib and buparlisib are two PI3K inhibitors that were evaluated in phase Ib trials in PDAC. The study on idelalisib was ended prematurely, however, due to severe toxicities encountered with this drug in other trials. Buparlisib showed no sign of efficiency in PDAC and was associated with frequent adverse events.

**Tumor cell metabolism.** PDAC displays specific metabolic features that may unveil therapeutic targets. Because of the fibrosis of their stroma, pancreatic cancer cells grow in an oxygen- and nutrient-deprived environment. Adaptations to this environment comprise an increased expression of glucose uptake systems, a dependence on autophagy to recycle molecular substrates, and a non-canonical use of certain amino acids such as glutamine. Hydroxychloroquine, an autophagy inhibitor, is currently evaluated in several trials, in association with extracellular signal-regulated kinase (ERK) inhibitors (NCT04386057) or with the MEK1/2 inhibitor binimetinib (NCT04132505). D,L-alpha-metyrosine is a tyrosine analogue that blocks protein synthesis in preclinical PDAC models, ultimately leading to apoptosis. In clinical trials, this drug is evaluated within an oral anticancer regimen called SM88. SM88 consists of: a mammalian target of rapamycin (mTOR) inhibitor (sirolimus), a CYP3A4 inducer (phenytoin), an oxidative stress catalyst (methoxsalen), and D,L-alpha-metyrosine, in PDAC. In a phase II trial in 49 patients with heavily pretreated metastatic PDAC, the disease control rate was only 24.3%; there were no partial or complete responses. An ongoing phase III trial will compare SM-88 with chemotherapy...
(gemcitabine + nab-paclitaxel or FOLFIRINOX) in first or second line (NCT04229004).

Altogether, targeted therapies in monotherapy failed to improve survival in unselected patients with metastatic PDAC. The genomic heterogeneity of PDAC, however, had led clinicians to evaluate personalized treatments. Precision oncology consists of treatment personalization based on the mutational profile of each patient.

Some 90% of PDACs carry a mutation in KRAS. Designing targeted therapies against KRAS represents a challenge, however, due to the absence of a targetable site on the KRAS protein. The main active site of KRAS is the GTP-binding site. A competitive inhibitor cannot be designed, however, due to the extreme affinity for GTP. In 2013, researchers described inhibitors binding to a pocket found specifically on the KRAS G12C-mutant protein.

The G12C mutant is infrequent in PDAC, with a prevalence of 1%-2%. Sotorasib, a KRAS G12C inhibitor, was approved by the EMA and FDA for the treatment of advanced lung tumors harboring KRAS G12C. In the phase I trial CodeBreak100, 38 patients with metastatic PDAC received sotorasib. Among them, 8 patients had a partial response, corresponding to an objective response rate of 21%, and 24 had stable disease. The disease control rate (stable disease + tumor response) was 84.2%. The median progression-free survival (PFS) was 4 months and the median OS 6.9 months in these heavily pretreated patients. Another ongoing trial is evaluating sotorasib in combination with chemotherapy in patients with unresectable or metastatic G12C-mutated PDAC (NCT04644068).

The phase I/II trial KRYS-1 evaluated adagrasib, another G12C inhibitor, in patients with advanced gastrointestinal tumors. Among the 10 assessable PDAC patients in this trial, 5 experienced a partial response and 5 had stable disease, with a median follow up of 6.3 months. Evidence suggests that recurrence occurs early in patients receiving a G12C inhibitor: progression results either from additional mutations impairing the binding of the inhibitor to KRAS, or from fusions affecting other genes of the MAP kinase pathway.

There is no inhibitor of other KRAS mutants, such as G12D or G12V, that has yet demonstrated clinical effectiveness in PDAC. An alternative strategy currently evaluated in clinical trials consists of inhibiting interaction partners of KRAS, such as SOS1 or SHP2: this may prevent KRAS activation in a mutation-independent manner (NCT04111458, NCT030369312). Other methods are being explored, such as small-interfering RNAs (siRNAs) inhibiting KRAS G12D (NCT01676239, NCT03086363). The relevance of this approach is limited, however, since siRNAs allow for a partial and transient inhibition of gene expression. Very recently, small molecule inhibitors of KRAS G12D have been discovered: these molecules will probably soon enter clinical trials.

Mutations in homologous repair genes (BRCA2, BRCA1, PALB2) are found in 15% of PDACs. Poly-ADP-ribose polymerase (PARP) is an enzyme involved in the recruitment of the DNA repair machinery to single-strand breaks. PARP inhibition leads to an accumulation of single-strand breaks that give rise to double-strand breaks after DNA replication. Therefore, PARP inhibitors are expected to have maximum efficiency in PDACs with homologous repair defects. POLO, a phase III trial, highlighted the efficiency of olaparib, a PARP inhibitor, as a maintenance treatment of metastatic PDAC in patients carrying a BRCA 1 or 2 germline mutation. The trial recruited patients whose disease did not progress after 16 weeks of first-line platinum-based chemotherapy. The median PFS was 7.4 and 3.8 months with olaparib and placebo ($P = 0.04$), respectively. Based on these results, the FDA approved olaparib for the maintenance treatment of germline BRCA-mutated metastatic PDAC. Final results of the POLO trial showed no difference in median OS between olaparib (19 months) and placebo (19.2 months; $P = 0.35$).

Several ongoing trials attempt to extend the use of PARP inhibitors to somatic BRCA variants or to patients displaying mutations in other genes. In a single-arm phase II trial, the PARP inhibitor rucaparib showed signs of efficiency as a maintenance therapy in patients with either somatic or germline mutations in BRCA1/2 or PALB2. The overall response rate was 41.7%, and median PFS and OS were 13.2 months and 23.5 months, respectively. Only 2 of the 42 patients, however, had somatic mutations. The ongoing MAZEPPA trial (NCT04348045) will evaluate olaparib in patients harboring a BRCA-ness phenotype resulting from somatic mutations.

Patients carrying germline mutations in BRCA1/2 or PALB2 also display increased responses to platinum-based chemotherapy. Indeed, cross-linking of platinum to DNA results in double-strand breaks. In a retrospective cohort of 26 patients carrying germline mutations, the overall response rate was doubled compared with matched controls (59% versus 28%, $P = 0.002$) with no difference depending on the platinum derivate used.

Mutations in BRAF are found mostly in KRAS wild-type PDACs, with a prevalence of 10%. Retrospective cohorts provide indirect evidence for the use of targeted therapies in these patients. Among 17 patients with BRAF-mutated PDACs treated with BRAF, MEK, or ERK inhibitors, the objective response rate was 53% and 36% of patients presented a partial response.

Larotrectinib, an NTRK1/2/3 inhibitor, was first tested in pediatric tumors where NTRK fusions are the main genetic driver. In a pooled analysis of trials, larotrectinib demonstrated tumor-agnostic activity, with 73% of adult patients experiencing a partial response and a median PFS of 28.3 months. This study, however, included only two PDACs. Entrectinib is another NTRK1/2/3 inhibitor with a broader inhibition spectrum also encompassing ALK and ROS1. In a phase II basket trial, three patients with metastatic PDAC carrying NTRK or ROS1 fusions received entrectinib: all experienced partial responses. Larotrectinib and entrectinib obtained FDA approval for the treatment of solid tumors displaying NTRK gene fusion.

Gene fusions involving neuregulin-1 (NGR1) result in aberrant expression of the EGF-like domain of NRG1 on the
cell surface, which serves as a ligand for human epidermal growth factor receptor 3 (HER3). This leads to pathologic activation of PI3K/AKT and MAP kinase pathways. NRG1 fusions are rare in PDAC (<1%). A phase II basket trial evaluated zenocutuzumab, a bispecific antibody targeting the HER3 pathway, in tumors harboring NRG1 fusions. Among 10 PDAC patients treated with zenocutuzumab, the overall response rate was 40% and the disease control rate reached 90%.43

To standardize the evaluation of precision oncology strategies, the European Society of Medical Oncology (ESMO) defined the ESCAT scale (ESMO Scale for Clinical Actionability of Molecular Targets). An ESCAT score of 1, corresponding to the best level of evidence, was attributed to three genomic alterations in PDAC: germline mutations in BRCA1/2 (IA), MSI-H status (IC), and NTRK fusions (IC).44

**Combination of targeted therapies and chemotherapy.** Combining targeted therapies with chemotherapy is a promising approach that could help overcome tumor resistance to targeted therapies. Table 3 presents ongoing trials testing this strategy in metastatic PDAC.

**Tumor cell proliferation.** Several trials combined chemotherapy with targeted therapies inhibiting MAP kinases. Erlotinib, an EGFR inhibitor, was evaluated with gemcitabine versus gemcitabine alone in locally advanced or metastatic PDAC. The median OS was improved by 10 days with combined therapy (6.24 versus 5.91 months, \( P = 0.038 \)). This benefit is statistically significant but was not considered clinically relevant by health authorities. Trametinib, a MEK inhibitor, combined with gemcitabine was not superior to gemcitabine alone.46 Overexpression of HER2 is identified in 10%-15% of PDACs. Trastuzumab in combination with capcitabine, however, showed no efficacy in metastatic PDAC.47 Anlotinib is a multitarget inhibitor targeting FGFRs, VEGFRs, and PDGFRs. In advanced PDAC, an ongoing trial is evaluating anlotinib in association with gemcitabine, nab-paclitaxel and a programmed cell death protein 1 (PD-1) inhibitor (NCT04718701). Similarly, a phase II trial evaluated the hyaluronidase PEGPH20 plus gemcitabine and nab-paclitaxel versus chemotherapy alone, in hyaluronan-high PDAC: there was no difference in OS or PFS between the two arms.50 Another candidate drug is pamrevlumab, an antibody directed against CTGF, a glycoprotein that plays a central role in fibrosis. An ongoing phase III trial is evaluating pamrevlumab in association with gemcitabine and nab-paclitaxel in metastatic PDAC (NCT04229004).

TGF-beta plays an ambiguous role in PDAC.52 On one hand, it exerts a tumor suppressive role by promoting cell cycle arrest. Consequently, TGF-beta signaling is impaired in 22% of PDACs through mutations in SMAD4. By contrast, TGF-beta has a pro-oncogenic effect on cancer-associated fibroblasts. An ongoing phase II study is evaluating the anti-TGF-beta monoclonal antibody NIS793 plus gemcitabine and nab-paclitaxel, versus chemotherapy alone, in metastatic PDAC (NCT04390763). A phase III trial with a similar experimental design started recruiting (NCT04935359).

Tumor microenvironment PDAC is characterized by a dense fibrotic stroma, called a desmoplastic reaction. Hyaluronan is a glycosaminoglycan that accumulates in the extracellular matrix in PDAC. A phase III trial evaluated the hyaluronidase PEGPH20 plus gemcitabine and nab-paclitaxel versus chemotherapy alone, in hyaluronan-high PDAC: there was no difference in OS or PFS between the two arms.50 Another candidate drug is pamrevlumab, an antibody directed against CTGF, a glycoprotein that plays a central role in fibrosis. An ongoing phase III trial is evaluating pamrevlumab in association with gemcitabine and nab-paclitaxel in metastatic PDAC (NCT04229004).
Finally, angiogenic factors such as VEGF could contribute to the pathogenesis of PDAC. Combining chemotherapy with anti-angiogenic agents such as bevacizumab or ramucirumab, however, was not superior to chemotherapy alone in patients with metastatic PDAC.54,55

| Drug | Target | Comparator | Patients | Phase | Status/trial ID |
|------|--------|------------|----------|-------|----------------|
| APG-1387 | IAP | No | M or LA, L ≥ 2 | I/II | Recruiting NCT04643405 |
| Selonexor | XPO1 | No | M, L ≥ 2 | II | Suspended NCT02178436 |
| Anlotinib | Multitarget TKI (FGFR2, VEGFR2) | No | M or LA, L2 | II | Recruiting NCT04718701 |
| Toripalimab | Anti-PD-1 | VEGFR1/2/3 | M, L1 | II | Recruiting NCT05168527 |
| Fruquintinib | GEM ABX | No | M, LA, L2 | II | Recruiting NCT02194829 |
| Adriamycin | CDK4/6 inhibitor | No | M, LA, L1 | II | Recruiting NCT05185869 |
| 9-ING-41 | GSK-3β | FOLFIRINOX | M, L1 | II | Recruiting NCT05077800 |
| CBP501 | Chk1 (G2 checkpoint) | Anti-PD-1 | Nivolumab | M, L3 >3 WBC <10G/L | II | Active, not recruiting NCT04953962 |
| Batiraxcept | GA56-AXL signaling | GEM ABX | M or LA | I/II | Recruiting NCT04983407 |
| Sotorasib | KRAS G12C | No | M or LA, L2 | I/II | Recruiting NCT05251038 |
| SHR6390 | P53 gene therapy | No | M or LA, L1 | II | Recruiting NCT02340117 |
| Tumor cell metabolism | Galeterone ± GEM Paricalcitol HCQ Evolocumab | Androgen receptor inhibitor Vitamin D analog Atorvastatin | No | M, L ≥ 3 | II | Recruiting NCT04698981 |
| ACE-031 | Anti-PD-1 | 3 Inhibitors of cholesterol metabolism | No | M, L1 | I | Recruiting NCT04524702 |
| Tumor micro-environment | Pamrevlumab + GEM ABX Racemetyllosine Carboplatin | CTGF Tyrosine metabolism | GEM ABX or mFOLFIRINOX | M, L1-2 | III | Recruiting NCT04229004 |
| NIS793 | VEGFR2 | GEM ABX | M or LA, L1 | I/II | Active, not recruiting NCT3745430 |
| GEM ABX | TGF-β signaling | Anti-PD1 | GEM ABX | M, L1 | II | Recruiting NCT04390355 |
| Spartalizumab | TGF-β signaling | GEM ABX | M, L1 | III | Recruiting NCT04933535 |
| GEM ABX | Hedgehog signaling | Anti-CTLA4 | No | M, L1 | II/III | Recruiting NCT04827953 |
| NIS793 | CEND1 | Drug transport | GEM ABX | M, L1 | II | Recruiting NCT05042128 |
| GEM ABX | Vactosertib | GEM ABX | M, L2 | I | Recruiting NCT04258072 |
| GEM ABX | TGF-β signaling | No | M, LA, L2 | I/II | Recruiting NCT04825288 |
| GEM ABX | IL-1α inhibitor | Nal-IRI + 5-FU | M or LA, L2 | I/II | Recruiting NCT042547448 |
| Epigenetics | Gemcitabine | DNA-methyltransferase | M, L1 | I/II | Recruiting NCT042547448 |

5-FU, 5-florouracil; ABX, nab-paclitaxel; CAIX, carbonic anhydrase IX; CTGF, Connective tissue growth factor; CDK, cyclin-dependent kinase; FGFR, fibroblast growth factor receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GEM, gemcitabine; HDAC, histone deacetylase; IL-1α, interleukin 1α; KRAS, Kirsten rat sarcoma viral oncogene homolog; L ≥ 2, second line or more; L1, first line; L2, second line; LA, locally advanced; M, metastatic; Nal-IRI, liposomal irinotecan; PO-1, programmed cell death protein 1; PDAC, pancreatic ductal adenocarcinoma; TGF-β, transforming growth factor-β; TKI, tyrosine kinase inhibitor; VEGFR, vascular endothelial growth factor receptor;
Altogether, combinations of targeted therapies with chemotherapy have not yet demonstrated clinical benefit in metastatic PDAC.

**Immunotherapy**

Cancer immunotherapy has attracted considerable attention due to the rise of checkpoint inhibitors. Other immunotherapies are emerging, however, such as therapeutic vaccines or chimeric antigen receptor (CAR) T cells. Ongoing trials evaluating immunotherapy in metastatic PDAC are reported in Supplementary Table S1, available at https://doi.org/10.1016/j.esmoop.2022.100638.

**Checkpoint inhibitors.** Checkpoint inhibitors are antibodies targeting cofactors of lymphocyte activation, such as PD-1, programmed death-ligand 1 (PD-L1) or CTLA4. These drugs demonstrated clinical benefit in several tumors, including colon and esophageal cancer. Checkpoint inhibitors in monotherapy, however, show no sign of efficacy in metastatic PDAC.56,67

Several mechanisms have been proposed to explain PDACs resistance to checkpoint inhibitors.68 First, lymphocyte activation requires the presence of tumor neoantigens. Tumors with a low TMB, such as pancreatic cancer, are less immunogenic. Beyond the TMB, tumors exhibiting dMMR have demonstrated increased sensitivity to checkpoint inhibitors. Consequently, the PD-1 inhibitor pembrolizumab obtained a tumor-agnostic approval for the treatment of dMMR tumors. In PDAC, however, the prevalence of dMMR is $<1\%$.15

Alternatively, checkpoint inhibitors possibly fail in PDAC due to the immunosuppressive microenvironment. Therefore, several trials are investigating combinations of checkpoint inhibitors with other therapies, with the aim to render the tumor sensitive to checkpoint blockade.59 A phase I/II trial evaluated the combination of ipilimumab, a CTLA4 inhibitor, with the PARP inhibitor niraparib as a maintenance therapy for metastatic patients with stable disease after 16 weeks of chemotherapy: 59.6% of patients were progression free after 6 months compared with a predefined endpoint of 44%. There was, however, no appropriate comparator arm in this study.60

**Therapeutic vaccines.** Therapeutic vaccines are designed to release a large amount of tumor antigens, in order to elicit tumor-specific immune responses. Existing vaccines are approved for the treatment of prostate cancer, bladder cancer, and melanoma. GV1001 is a peptide vaccine derived from hTERT, an enzyme overexpressed in PDAC. The phase III TELOVAC trial evaluated the addition of GV1001 to a chemotherapy regimen combining gemcitabine and capectabine, versus gemcitabine and capectabine alone. The trial, which included 1062 treatment-naïve patients with locally advanced or metastatic PDAC, was negative.61 Another phase III trial tested the combination of GV1001 and chemotherapy in patients with elevated eotaxin. Patients in the control arm received gemcitabine and capectabine alone. The trial was positive, with a median OS of 11.3 and 7.5 months in the experimental and control arms, respectively ($P = 0.021$).62

**Adaptive cell therapy.** Adaptive cell therapy consists of the in vitro expansion and reinfusion of autologous immune cells. For example, CAR T cells are lymphocytes engineered to express a receptor directed against a tumor-specific antigen. Lymphocytes collected from the patient by leukapheresis are genetically modified to express CARs, and then reinjected to the patient. Attempts to generate CAR T cells against solid tumors, however, have faced several challenges. Contrary to lymphomas, solid tumors do not express highly specific antigens: certain ‘tumor-associated antigens’, are overexpressed in solid tumors, but they are also expressed at lower levels in normal tissues. This lack of specificity results in a reduced homing of CAR T cells to the tumor.63 The immunosuppressive tumor microenvironment also contributes to the insufficient homing of infused cells to the tumor.

Claudin-18 is a protein involved in tight junction formation. The Claudin 18.2 isoform is overexpressed in 50%-70% of PDACs. An early phase I study evaluated Claudin 18.2-specific CAR T cells in advanced Claudin 18.2-positive pancreatic or gastric cancers. Patients received one to five cycles of a lymphodepletion pretreatment with or without nab-paclitaxel followed by CAR T cell infusion. A total of 12 patients were included (7 gastric cancers and 5 PDACs). Among them, one patient with gastric cancer had a complete response and three showed partial responses (two gastric adenocarcinomas and one PDAC).64 The objective response rate was 33.3%.

**CONCLUSION**

To date, the largest gain in life expectancy for patients with metastatic PDAC came from chemotherapy with FOLFIRINOX or gemcitabine-nab-paclitaxel: these regimens expanded the median OS from 4 to nearly 12 months. Targeted therapies provide no benefit in unselected patients with metastatic PDAC. They are, however, efficient in PDACs carrying specific mutations, such as: mutations affecting DNA homologous repair, KRAS wild-type PDAC, or the KRAS G12C mutant. Combining chemotherapy with targeted therapies has not yet demonstrated a clinical benefit in metastatic PDAC. Available immunotherapies are not efficient in PDAC, but this paradigm could potentially change due to the development of alternative approaches such as therapeutic vaccines or CAR T cells.

**FUNDING**

None declared.

**DISCLOSURE**

The authors have declared no conflicts of interest.

**REFERENCES**

1. Globocan 2020. Available at https://gco.iarc.fr/today/data/factsheets/populations/908-europe-factsheets.pdf. Accessed November 9, 2022
2. Huang J, Lok V, Ngai CH, et al. Worldwide burden of, risk factors for, and trends in pancreatic cancer. Gastroenterology. 2021;160:744-754.
3. Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol. 2016;55:1158-1160.

https://doi.org/10.1016/j.esmoop.2022.100638
4. National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program. National Cancer Institute. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html. Accessed November 9, 2022.

5. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit of gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.

6. von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691-1703.

7. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-1825.

8. Wang-Gillam A, Hubner RA, Siveke JT, et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019;108:78-87.

9. Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545-557 (2016).

10. Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 2017;32: 185-203.e13.

11. Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495-501.

12. Wu HX, Wang ZX, Zhao Q, et al. Tumor mutational and indel burden: a biomarker. Gastroenterology. 2020;158:849-860.e2.

13. Marabelle A, Fakih M, Lopez J, et al. Association of tumor mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-185 study. Lancet Oncol. 2020;21:1353-1365.

14. McGrail DJ, Pilié PG, Rashid NU, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021;32:661-672.

15. Singh AD, George B, Greenbowe JR, et al. Real-time targeted genome analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Gastroenterology. 2019;156:2242-2253.e4.

16. Mehdi M, Kamgar M, George B, et al. Impact of KRAS alterations in pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2021;39:4136.

17. Tan H, Baca Y, Xiou J, et al. Impact of somatic SWI/SNF alterations on the genomic landscape of pancreatic ductal adenocarcinoma and response to PARP and immune checkpoint inhibitor therapy. J Clin Oncol. 2022;40:e16289.

18. Borzaci E, Pishvaian MJ, Nemunaitis J, et al. A phase Ib study of single-agent idelalisib followed by idelalisib in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma. Oncologist. 2020;25:e1604-e1613.

19. Encarnación-Rosado J, Kimmelman AC. Harnessing metabolic dependencies in pancreatic cancers. Nat Rev Gastroenterol Hepatol. 2021;18:482-492.

20. Noel MS, Kim S, Hartley ML, et al. A randomized phase II study of SM -88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond. Cancer Med. 2022. https://doi.org/10.1002/cam4.4768.

21. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM, G-RAS (G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548-551.

22. Sotorasib tackles KRASG12C-mutated pancreatic cancer. Cancer Discov. 2022;12:878-879.

23. Mehdi M, Kamgar M, Ramharter J, Sukari A, Azmi AS, Ou SI. Bl 3406, a potent and selective SOS1—KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. Cancer Discov. 2021;11:142-157.

24. Golan T, Khvalevsky EZ, Hubert A, et al. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget. 2015;6:24560-24570.

25. Wang X, Allen S, Blake JF, et al. Identification of MRTX1133, a non-covalent, potent, and selective KRASG12C inhibitor. J Med Chem. 2022;65:3132-3133.

26. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA –mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317-327.

27. Golan T, Hammel P, Reni M, et al. Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol. 2021;39:378.

28. Reiss KA, Mick R, O’Hara MH, et al. Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2. J Clin Oncol. 2021;39:2497-2505.

29. Wattenberg MM, Asch D, Yu S, et al. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer. 2020;122:333-339.

30. Pishvaian MJ, Garrido-Laguna I, Liu SV, Multani PS, Chow-Maneval E, Rolfo C. Entrectinib in TRK and ROS1 fusion-positive metastatic pancreatic cancer. JCO Precis Oncol. 2018;2:1-7.

31. Schram AM, O’Reilly EM, O’Kane GM, et al. Efficacy and safety of necitumumab in advanced pancreas cancer and other solid tumors harboring NR1G1 fusions. J Clin Oncol. 2021;39:3003.

32. Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2021;32:1491-1505.

33. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
46. Infante JR, Somer BG, Park JO, et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. *Eur J Cancer*. 2014;50:2072-2081.

47. Harder J, Ihorst G, Heinemann V, et al. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. *Br J Cancer*. 2012;106:1033-1038.

48. Sha S-K, Sato T, Kobayashi H, et al. Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint. *Mol Cancer Ther*. 2007;6:147-153.

49. Mine N, Yamamoto S, Saito N, et al. CBP501-calmodulin binding contributes to sensitizing tumor cells to cisplatin and bleomycin. *Mol Cancer Ther*. 2011;10:1929-1938.

50. Singhal N, Sigal D, Tebbutt NC, et al. SBP-101, a polyamine metabolic inhibitor, administered in combination with gemcitabine and nab-paclitaxel, shows signals of efficacy as first-line treatment for subjects with metastatic pancreatic ductal adenocarcinoma. *J Clin Oncol*. 2021;39:4127.

51. Van Cutsem E, Tempero MA, Sigal D, et al. Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma. *J Clin Oncol*. 2020;38:3185-3194.

52. Neuzillet C, Tijeras-Raballand A, Cohen R, et al. Targeting the TGFβ pathway for cancer therapy. *Pharmacol Ther*. 2015;147:22-31.

53. Quatannens D, Verhoeven Y, Van Dam P, et al. Targeting hedgehog signaling in pancreatic ductal adenocarcinoma. *Pharmacol Ther*. 2022;236:108107.

54. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. *J Clin Oncol*. 2009;27:2231-2237.

55. Shaib WI, Rupji M, Khair TA, et al. Phase II randomized, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198). *J Clin Oncol*. 2021;39:413.

56. O’Reilly EM, Oh D-Y, Dhani N, et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. *JAMA Oncol*. 2019;5:1431.

57. Renouf DJ, Knox JJ, Kavan P, et al. LBA65 The Canadian Cancer Trials Group PA.7 trial: results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC). *Ann Oncol*. 2020;31:S1195.

58. Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? *Am Soc Clin Oncol Educ Book*. 2019;39:147-164.

59. O’Hara MH, O’Reilly EM, Wolf R, et al. Gemcitabine (Gem) and nab-paclitaxel (NP) ± nivolumab (nivo) ± CD40 agonistic monoclonal antibody APX005M (sotigalimab), in patients (Pts) with untreated metastatic pancreatic adenocarcinoma (mPDAC): Phase (Ph) 2 final results. *J Clin Oncol*. 2021;39:4019.

60. Reiss KA, Mick R, Teitelbaum U, et al. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. *Lancet Oncol*. 2022;23:1009-1020.

61. Middleton G, Silcocks P, Cox T, et al. Gemcitabine and capcetabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. *Lancet Oncol*. 2014;15:829-840.

62. Jo JH, Kim Y-T, Choi HS, et al. KG 4/2015: A randomized, controlled, multicenter, open-label phase III clinical trial of GV1001 with gemcitabine/capcetabine in previous untreated, eotaxin-high patients with advanced pancreatic ductal adenocarcinoma. *J Clin Oncol*. 2021;39:4020.

63. Martinez M, Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. *Front Immunol*. 2019;10:128.

64. Zhan X, Wang B, Li Z, et al. Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma. *J Clin Oncol*. 2019;37:2509.